Mortality from pancreatic ductal adenocarcinoma (PDAC) has remained essentially unchanged for decades and its relative contribution to overall cancer death is projected to only increase in the coming years. Current treatment for PDAC includes aggressive chemotherapy and surgical resection in a limited number of patients, with median survival of optimal treatment rather dismal. Recent advances in gene therapies offer novel opportunities for treatment, even in those with locally advanced disease. In this review, we summarize emerging techniques to the design and administration of virotherapy, synthetic vectors, and gene-editing technology. Despite these promising advances, shortcomings continue to exist and here will also be highlighted those approaches to overcoming obstacles in current laboratory and clinical research.
Bibliographical noteFunding Information:
This work was partly supported by Award Numbers R01CA196215 (Masato Yamamoto) and R01CA168448 (Masato Yamamoto). Keith Wirth is supported by NIH/NIDDKT32DK108733 (MPI: Yamamoto and Beilman).
© 2018 by the authors. Licensee MDPI, Basel, Switzerland.
- Non-viral vector
- Pancreatic adenocarcinoma
- Pancreatic cancer
- RNA interference